Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of anxiety disorders
3.2.1.2 Rising geriatric population
3.2.1.3 Increased incidence of insomnia
3.2.1.4 Advancements in drug formulations
3.2.2 Industry pitfalls & challenges
3.2.2.1 Associated side effects
3.2.2.2 Abuse potential and regulatory restrictions
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2018 – 2032 ($ Million)
5.1 Key trends
5.2 Alprazolam
5.3 Diazepam
5.4 Lorazepam
5.5 Clonazepam
5.6 Temazepam
5.7 Oxazepam
5.8 Chlordiazepoxide
5.9 Other products
Chapter 6 Market Estimates and Forecast, By Drug Class, 2018 – 2032 ($ Million)
6.1 Key trends
6.2 Ultra-short acting
6.3 Short acting
6.4 Long acting
Chapter 7 Market Estimates and Forecast, By Indication, 2018 – 2032 ($ Million)
7.1 Key trends
7.2 Anxiety
7.3 Insomnia
7.4 Alcohol withdrawal
7.5 Seizures
7.6 Other indications
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Million)
8.1 Key trends
8.2 Oral
8.3 Parenteral
8.4 Other routes of administration
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Million)
9.1 Key trends
9.2 Hospital pharmacy
9.3 Retail drug stores
9.4 Online pharmacy
Chapter 10 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Million)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AbbVie Inc.
11.2 Amneal Pharmaceuticals LLC.
11.3 Bausch Health Companies Inc.
11.4 Boehringer Ingelheim International GmbH
11.5 F. Hoffmann-La Roche Ltd.
11.6 GlaxoSmithKline Plc.
11.7 Hikma Pharmaceuticals PLC
11.8 Mylan N.V.
11.9 Novartis AG
11.10 Pfizer Inc.
11.11 Sanofi
11.12 Teva Pharmaceutical Industries Ltd.
